Naratuximab

CAS No. 1622327-39-2

Naratuximab( —— )

Catalog No. M37306 CAS No. 1622327-39-2

Naratuximab emtansine is a humanized monoclonal antibody (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) that specifically targets CD37 (TSPAN26) and serves as the basis for creating an antibody-drug conjugate (ADC) compound.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 363 Get Quote
5MG 751 Get Quote
10MG 1197 Get Quote
25MG 1720 Get Quote
50MG 2318 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Naratuximab
  • Note
    Research use only, not for human use.
  • Brief Description
    Naratuximab emtansine is a humanized monoclonal antibody (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) that specifically targets CD37 (TSPAN26) and serves as the basis for creating an antibody-drug conjugate (ADC) compound.
  • Description
    Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ADC Antibody
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1622327-39-2
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Stuart W Hicks, et al. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 2017 Sep;19(9):661-671.?
molnova catalog
related products
  • TRH, Free Acid

    TRH, Free Acid

  • [D-Arg6,Asn10]-MCH (...

    [D-Arg6,Asn10]-MCH (6-16) amide (human, mouse, rat)

  • Sepin-1

    Sepin-1 is a noncompetitive inhibitor of separase with an IC50 of 14.8 μM. Sepin-1 can inhibit the growth of breast cancer xenograft tumors in mice and human cancer cell lines by inhibiting cell proliferation and inducing apoptosis.